**Quality of life and sleep profile in relapsing remitting multiple sclerosis patients**

**Abstract:**

**Background:** Multiple sclerosis (MS) is the most common demyelinating autoimmune disease affecting the central nervous system (CNS) which can present by various neurological symptoms including visual impairment, numbness and tingling, focal weakness, bladder and bowel incontinence and cognitive dysfunction. Patients with MS rate their health-related quality of life (HRQOL) to be lower than that of the general populations and also lower than patients with other chronic diseases such as epilepsy and diabetes. Patients with multiple sclerosis (MS) frequently report poor sleep, and sleep disorders are more common in MS patients compared to the healthy group. **Aim of the work:** The aim of the current study was to assess the quality of life and sleep profile in patients with relapsing remitting multiple sclerosis (RRMS). **Methods**: The studywas descriptive comparative case control study which included 40 patients and 40 controls; HRQOL was assessed using the Arabic version of the Multiple Sclerosis Quality of Life-54 questionnaire in RRMS patients. Sleep quality was assessed for both patients and control group using the Arabic version of The Pittsburgh Sleep Quality Index. To measure patients’ degree of disability, the Expanded Disability Status Scale (EDSS) was used. **Results:** The results showed that RRMS patients have low mean physical and mental composite score. The results also showed that RRMS patients have high global sleep index indicating poor sleep quality. **Conclusion:** MS patients have limitations as regard physical and cognitive functions in addition to poor sleep quality, which lead to low health related quality of life.

**Keywords:** multiple sclerosis, health related quality of life, sleep quality, disease severity.

**Introduction:**

Multiple sclerosis is an autoimmune-mediated disorder that affects the central nervous system (CNS) which is considered a leading neurological cause of disability in some populations **(1).** The incidence and prevalence of MS has been on an alarming rise **(2).**

The causes of the disease are not exactly known, but there are genetic and environmental factors such as vitamin D deficiency, Epstein-Barr virus, and Herpes virus infections that activate T cells and lead to myelin sheath destruction **(3)**.

The clinical manifestations differ depending on the site of the lesion in the CNS and the phenotype of MS. The common clinical presentations are visual loss, sensory loss including numbness and tingling, weakness, incoordination, imbalance, gait impairment and bladder/ bowel dysfunction **(4).**

Types of MS depend on the progression, deterioration and remission of the disease. They include the relapsing-remitting form multiple sclerosis (RRMS), primary progressive MS (PPMS), secondary progressive MS (SPMS), clinically isolated syndrome and radiological isolated syndrome. The most common type is the relapsing remitting type (RRMS) as it affects approximately 85% of the MS population **(5).**

Studies involving MS patients have shown that wellbeing is not a simple manifestation of impairment or disability **(6).** The quality of life in multiple sclerosis patients depends on many factors such as the type of MS, type of treatment, social relationships, social support and psychological **(7).**

MS patients rate their health related QOL lower than general populations and also lower than patients with other chronic diseases such as epilepsy and diabetes **(8)**. There is a growing interest in how different problems associated with MS, such as fatigue and depression, impact different dimensions of QOL independent of the contribution of physical disability **(9).**

Multiple sclerosis patients frequently report poor sleep and many studies revealed that sleep disorders are more common in MS patients compared to healthy individuals (**10).** Causes of poor sleep in MS are multifactorial including adverse effects from immunotherapy, symptomatic medications, MS-associated symptoms such as pain and fatigue **(11).**

Patients suffering from sleep disturbance have an increased risk of developing co-morbid conditions such as heart disease, obesity and diabetes that may have a profound impact on long-term health. In order to improve sleep and possibly reduce long-term health consequences of poor sleep in MS, identification of modifying risk factors of poor sleep is needed **(12).**

**Subjects and methods:**

This was a descriptive comparative case control study carried out among RRMS patients from the MS outpatient clinic at Benha University Hospitals and from MS committee at Benha insurance hospital, from the end of 2021 till the end of March 2023. Patients between 18 and 60 years with RRMS according to McDonald criteria **(13)** were included in the study.Other types of MS patients, patients who had relapse within the last 3 months and patients with comorbid diseases were excluded. As for the control group, a matched sample for age and sex were selected. The included patients filled a semi structured interview containing questions about age, sex, marital status, educational lev­el and employment status. To measure patients’ disability status, we used the Expanded Disability Status Scale (EDSS) **(14)**. Patients were categorized according to the total EDSS score as having mild (0–2.5), moderate (3.0–6.0), and severe (6.5- 9.5) disability. HRQOL was assessed using the MSQoL-54 questionnaire which is a disease-specific instrument to measure the QOL of MS patients, which was based on the generic SF-36 QOL instrument. Two composite scores can be obtained on the MSQOL-54, physical health composite and mental health composite **(15).** Quality of sleep was assessed in both patients and controls using the Pittsburgh Sleep Quality Index (PSQI) **(16)** which assesses sleep quality over a 1-month time interval. The Arabic version of this questionnaire was used **(17).** The measure consists of 19 individual items, creating 7 components each weighted equally on 0-3 scale. They are summed to yield a global PSQI score which has a range of 0-21; higher scores indicated worse sleep quality.

**Research ethics committee: Ms.44.12.2021.**

**Statistical analysis:**

The collected data was revised, coded and tabulated using Statistical package for Social Science (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.). Data were presented and suitable analysis was done according to the type of data obtained for each parameter.

Descriptive statistics such as Mean, standard deviation (± SD), median, standard error (±SE), and range were used for numerical data. Frequency and percentage were used for non-numerical data. Student T Test was used to assess the statistical significance of the difference of parametric variable between two study group means. Mann Whitney Test was used to assess the statistical significance of the difference of a non-parametric variable between two study groups.

**Results:**

This studypresents comparative statistics for the socio demographic data including age, sex, marital status, educational level and occupation between the two groups. The majority of MS patients were females (72.5%), below the age of 40 (67.5%), married (62.5%). The study showed no statistically significant difference between patients with multiple sclerosis and control group regarding age, sex and marital status. The results also show that most of MS patients were university graduate (52.5%) and had professional job (42.5%). There was no significant difference between the MS and control groups regarding education and occupation (p≥0.05) **(Table 1).** The majority of the MS group (75.0%) lived in urban areas in contrast to the control group in which the majority (62.5%) lived in rural areas with a high statistical significant difference.

The mean duration of illness in the studied MS group was 5.26 ± 0.57 years. The median of the duration of illness was 5 years, and the range was from 0.5 to 19.0 years (**Table 2**).

The results also revealed that the most commonly used medication is Fingolimod (47.5%) followed by Interferon b 1a (17.5%) then Rituximab (12.5%) (**Table 3**).

The mean EDSS score for the MS patients was 1.91 ± 0.30, with 85% having mild disability, while the remaining 15% had moderate disability. The functional systems with the highest mean scores were pyramidal and mental, with scores of 0.95 ± 0.22 and 0.63 ± 0.11, respectively (**Table 4**).

The mean physical composite score for the MS patients were 50.28 ± 3.47. As for its the subscales; the lowest mean scores were role limitation due to physical problem, health distress due to physical problems and energy, with scores of 3.0 ± 0.75, 5.57 ± 0.50 and 5.72 ± 0.41, respectively. The subscales with the highest mean scores were physical function, health perception and social function, with scores of 7.88 ± 0.87, 8.05 ± 0.51 and 7.48 ± 0.47, respectively as shown in **table 5.**

Regarding the mental composite score, the mean was of 46.42 ± 3.36. As for its subscales, the lowest mean score was cognitive function 5.44 ± 0.56 and the highest was emotional well-being (13.57 ± 1.05) as shown in **table 6.**

PQSI questionnaire scores from both MS patients and the control group were compared. MS patients had a higher mean global PSQI score (7.40 ± 0.66) compared to controls (5.98 ± 0.54), indicating poorer sleep quality. There was a significant difference (p=0.031) between the two groups in terms of sleep efficiency, with the MS group reporting a higher mean score (0.58 ± 0.15) compared to the control group (0.20 ± 0.09). Most of MS patients (75%) were classified as poor sleeper which was insignificantly higher than the control group (67.5%). There were also no significant differences between the two groups in terms of subjective sleep quality, sleep latency, sleep duration, sleep disturbance, sleep medication, and daytime dysfunction **(Table 7).**

**Discussion:**

Multiple sclerosis (MS) is a chronic autoimmune central nervous disease (CNS) characterized by inflammation, demyelination, gliosis and neuronal loss. Pathological perivascular lymphocytic infiltrates and macrophages produce degradation of myelin sheaths that surround neurons **(18).** Neurological symptoms vary depending on lesion location and can include visual impairment, numbness and tingling, focal weakness, bladder and bowel incontinence and cognitive dysfunction**(19).**

MS affects the quality of life of patients compared to the general population and those with other chronic diseases. Lower QOL interferes with a patient’s ability to work, pursue leisurely activities and perform daily life tasks.Sleep disturbances are observed four times more frequently in MS patients compared to the general population. The estimated prevalence ranged from 25% to 62%, with a higher prevalence in women. Appropriate sleep regularity, duration and absence of sleep disturbances are important for healthy sleep and good quality of life **(20).**

The current study demonstrated that the mean age of MS patients was 35.23 years and the majority of MS patients (67.5%) were ≤40 years old and the remaining (32.5%) were >40 years old. The results also revealed that 72.5% of MS patients were females while 27.5% were males. There was no statistically significant difference between MS patients and control group regarding age, sex and marital status as shown in **table 1.** This could be explained by the fact that MS onset occurs typically in adults with peak age at onset between 20–40 years and there is a female predominance of up to 3:1 ratio **(21).** The present results also indicated that there was no significant difference between MS patients and the control group regarding education and occupation **(Table 1).**

The current study showed that the majority of the MS group (75.0%) lived in urban areas in contrast to the control group in which the majority (62.5%) lived in rural areas with a high statistical significant difference **(Table 1)**. This is explained by the fact that living in urban areas increases the incidence for MS disease duo to environmental factors such as lack of sun exposure and CO pollution, also urban living allows better access to health care facilities.

In the same line with the present results, **Balakrishnan et al. (22)** had revealed that in a total of 1557 patients with MS; 81.7% were female, 18.3% were male, with a minimum of 18 years, maximum of 76 years and mean of 46 years.

The present results were also in same line with **Al-Abdullah et al. (23)**who had identified 82 patients with MS, they revealed that the majority of cases were married and their education level was that of high school with no significant difference regarding marital status and education level as well as occupation **(Table 1).**

The present study also revealed that the mean duration of illness was 5.26 ± 0.57 years, ranged from 0.5 to 19.0 years **(Table 2)**. **Al-Abdullah et al. (23)** had similar results in their study as the mean disease duration was 4.07±3.65 years. This could be due to the advances in recent years in the diagnosis and increasing awareness among medical staff and the community which lead to diagnosing the disease at a younger age.

The most commonly prescribed medication in the studied RRMS patients was the oral treatment Fingolimod (47.5%), followed by the injection of Interferon b 1a (17.5%) and Rituximab (12.5%). The remaining medications were used by fewer than five individuals in the sample **(Table 3).**

**Kołtuniuk and his colleagues (24)** revealed that in cases with RRMS, an injection of interferon (IFN)-β1b was the most commonly used drug amoung 107 of their patients, IFN-β1a in 94 patients, and glatiramer acetate in 34 patients. The oral treatment includes teriflunomide in 14 patients, dimethyl fumarate in 86 patients, and fingolimod in nine patients.

The discrepancy with the current results may be due to the recommendation of the Egyptian society of MS which guide the prescription of medication according to the clinical picture, number of relapses among RRMS patients, availability and cost of the medications.

The mean EDSS score for the sample was 1.91 ± 0.30. The median EDSS score was 1.50, and the range was from 0 to 6. The functional systems with the highest mean scores were pyramidal and mental, with scores of 0.95 ± 0.22 and 0.63 ± 0.11, respectively, followed by sphincter, sensory, visual, cerebellar and brainstem with scores of 0.50 ± 0.08, 0.33 ± 0.08, 0.18 ± 0.07, 0.13 ± 0.06 and 0.0 ± 0.0 respectively. The majority of MS patients in the sample 85% had mild disability, while the remaining 15% had moderate disability **(Table 4)**.

Another Egyptian study performed by **Khedr and other researchers**, had revealed that the mean EDSS score was 2.93 ± 1.86 SD with a range of 0.50 to 6.50, with the most common initial presenting symptom was motor symptoms related to the pyramidal system involvement which agreed with the results of this research, followed by sensory symptoms and optic nerve involvement **(25).**

The current study showed that the mean physical composite score for the MS patients was 50.28 ± 3.47; the subscales with the lowest mean scores were role limitation due to physical problem indicating that MS patients experience some limitations in their ability to perform daily physical activities, followed by health distress due to physical problems with scores 3.0 ± 0.75 and 5.57 ± 0.50 respectively. The subscales with the highest mean scores were physical function and health perception with scores 8.05 ± 0.51 and 7.88 ± 0.87 respectively. While the present study revealed that mean scores for energy, pain, sexual function and social function were 5.72 ± 0.41, 5.81 ± 0.51, 6.70 ± 0.40 and 7.48 ± 0.47 respectively. This indicates that individuals in the sample experience pain and fatigue related to their MS symptoms **(Table 5).**

As shown in **table 6**, MS patients had a mean mental composite score of 46.42 ± 3.36; the subscale with the lowest score was cognitive function with score 5.44 ± 0.56 indicating that MS patients have difficulty concentrating and thinking, troubles keeping their attention for long and troubles with their memory, followed by health distress due to emotional problems with score 7.09 ± 0.64. The highest mean score was emotional wellbeing with score of 13.57 ± 1.05. The role limitation due to emotional problem score was 10.0 ± 1.85, indicating that the patients had cut down the time they spent on work of activities due to emotional problems.

**Visser et al.** were in agreement with the current study as they revealed that the mean MSQOL-54 physical health composite score and mental health composite scale for the MS patients was 42.5 (SD: 17.2) and 58.3 (SD: 21.5), respectively **(26).**

Regarding the mean global sleep index score for the MS group in the present study was 7.40 ± 0.66, which was insignificantly higher than the control group with a mean score 5.98 ± 0.54 and most of MS patients (75%) were classified as poor sleeper which was insignificantly higher than the control group (67.5%) (**Table 7).**

This can be explained by the fact that the majority of the control group was students and medical staff with frequently changing sleeping hours which resulted in poor sleep quality. The most frequent causes of poor sleep in the studied group of MS patients are physical complaints such as musculoskeletal pain and muscular spasticity. Nocturia and urgency lead to interrupted sleep with difficulty falling back into sleep again thus considered major contributing factors to the poor sleep quality **(table 7).**

In the same line with **Bøe Lunde et al. (27)** who found that patients with MS showed a higher mean global sleep score than controls (8.6 versus 6.3), and 67.1% of the MS patients compared to 43.9% of the controls were poor sleepers. Also In the same line with an Egyptian study by **Abd Elsadek et al. (28)** who found that patients with RRMS showed a higher mean global sleep score than controls (6.3 versus 4.5) and Nineteen MS patients (76%) had poor sleep quality.

The present study revealed a significant difference between the two groups in terms of sleep efficiency which is defined as the percentage the number of hours slept divided by the numbers of hours spent in bed, with the MS group reporting a higher mean score (0.58 ± 0.15) compared to the control group (0.20 ± 0.09). There was no significant difference between the two studied groups regarding the subjective sleep quality, sleep latency, sleep duration, sleep disturbance, sleep medication, and daytime dysfunction **(Table 7).**

On the other hand, a study done by **Bøe Lunde et al. (27)**found that PSQI sleep onset latency was significantly higher (1.4±1.1) among patients than controls (1.1±1.1). Another study by **Buratti et al.** found thatpatients with MS showed a worse sleep quality, in terms of duration, efficiency, and architecture compared to healthy subjects **(29).**

That is why early identification and treatment of modifiable risk factors affecting sleep quality in patients suffering from MS is mandatory in order to improve sleep and quality of life in general.

**Conclusion:**

In conclusion, multiple sclerosis has negative impact on both physical and mental function. MS patients have limitations as regard physical and cognitive functions which, in addition to poor sleep quality, lead to low health related quality of life. We recommend conducting further research including different types of MS and correlating between duration of illness, number of relapses, medication used, quality of life and quality of sleep.

**Reference:**

1. **Karussis D.:** The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun.2014; 48–49:134–42.
2. **Marrie RA, Cohen J, Stuve O, Trojano M, Sørensen PS, Reingold S:** A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler.2015;21(3):263–81
3. **Tiwari S, Lapierre J, Ojha CR, Martins K, Parira T, Dutta RK,et al.**: Signaling pathways and therapeutic perspectives related to environmental factors associated with multiple sclerosis. J Neurosci Res. Dec 2018; 96(12):1831-1846.
4. **Gelfand JM.:** Multiple sclerosisdiagnosis, differential diagnosis, and clinical presentation. HandbClin Neurol.2014; 122:269–90.
5. **Berkovich RR. :** Acute Multiple Sclerosis Relapse, Continuum (Minneap Minn). Jun 2016; 22(3):799-814.
6. **Benito-Leon J, Morales JM, Rivera-Navarro J:** A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil; 2003; 25:1291–303
7. **Sabanagic-Hajric S, Suljic E, Memic-Serdarevic A, Sulejmanpasic G, Mahmutbegovic N.:** Quality of Life in Multiple Sclerosis Patients: Influence of Gender, Age and Marital Status. Mater Sociomed. Mar 2022; 34(1):19-24.
8. **Ford H, Gerry E, Johnson M:** Health status and quality of life of people with multiple sclerosis. Disabil Rehabil. 2001; 23:516–21.
9. **Bakshi R.:** Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler. Jun 2003; 9(3):219-27.
10. **Merlino G, Fratticci L, Lenchig C, Valente M, Cargnelutti D:** Prevalence of ‘poor sleep’ among patients with multiple sclerosis: an independent predictor of mental and physical status. Sleep Med. 2009; 10: 26–34.
11. **Brass SD, Duquette P, Proulx-Therrien J, Auerbach S**: Sleep disorders in patients with multiple sclerosis. Sleep Med Rev. 2010; 14: 121–129.
12. **Kaminska M, Kimoff R, Benedetti A, Robinson A, Bar-Or A:** Obstructive sleep apnea is associated with fatigue in multiple sclerosis. MultScler. Aug 2011; 18(8):1159-69.
13. **Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al.:** Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. Feb 2018; 17(2):162-173.
14. **Kurtzke JF:** Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983*;* 33:1444-52.
15. **Vickrey, B.G., Hays, R.D., Harooni, R., Myers L. W., Ellison G. W. ():** A health-related quality of life measure for multiple sclerosis. Qual Life Res*.* 1995; 4: 187–206.
16. **Buysee DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ:** The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research.1989; 28:193-213.
17. **Khaled Suleiman, Bernice Yates, Ann Berger, Bunny Pozehl , Jane Meza.:** Translating the Pittsburgh Sleep Quality Index into Arabic. Western journal of nursing research. 2009; 32. 250-68. 10.1177/0193945909348230.
18. **Tafti D, Ehsan M, Xixis KL.:** Multiple SclerosisIn: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing: Jan2023. [Updated 2022 Sep 7].
19. **Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, et al.:** International Advisory Committee on Clinical Trials in Multiple Sclerosis. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. Jan 2023; 22(1):78-88.
20. **Hirshkowitz M, Whiton K, Albert SM, Alessi C, Bruni O, DonCarlos L, et al.:** National Sleep Foundation's sleep time duration recommendations: methodology and results summary. Sleep Health. Mar 2015; 1(1):40-43.
21. **Helen Ford:** Clinical presentation and diagnosis of multiple sclerosis. Clin Med (Lond). Jul 2020; 20(4):380-383.
22. **Balakrishnan P, Groenberg J, Jacyshyn-Owen E, Eberl M, Friedrich B, Joschko N. et al.:** Demographic Patterns of MS Patients Using BRISA: An MS-Specific App in Germany. J Pers Med. Jul 2022; 12(7):1100.
23. **Al-Abdullah MS, Siddiqui AF.:** Demographic and disease characteristics of multiple sclerosis in the Southwest Region of Saudi Arabia. Neurosciences (Riyadh). Oct 2018; 23(4):320-325.
24. **Koltuniuk A, Pawlak B, Krówczyńska D, Chojdak-Łukasiewicz J:** The quality of life in patients with multiple sclerosis. Association with depressive symptoms and physical disability: A prospective and observational study. Front. Psychol. 2023; 13:1068421
25. **Khedr EM, El Malky I, Hussein HB, Mahmoud DM, Gamea A.:** Multiple sclerosis diagnostic delay and its associated factors in Upper Egyptian patients. Sci Rep. Feb 2023; 13(1):2249.
26. **Visser LA, Louapre C, Uyl-de Groot CA, Redekop WK.:** Health-related quality of life of multiple sclerosis patients: a European multi-country study. Arch Public Health. Mar 2021; 79(1):39.
27. **Bøe Lunde HM, Aae TF, Indrevåg W, Aarseth J, Bjorvatn B, Myhr KM, Bø L.:** Poor sleep in patients with multiple sclerosis. PLoS One.; 2012; 7(11):e49996.
28. **Abd Elsadek, S., Maabady, M., Shafik, M.:** 'Sleep Disorders in Egyptian MS Patients: Clinical and Polysomnography Study', the Egyptian Journal of Hospital Medicine, 2019; 75(5), pp. 2921-2929.
29. **Buratti L, Iacobucci DE, Viticchi G, Falsetti L, Lattanzi S, Pulcini A, et al.:** Sleep quality can influence the outcome of patients with multiple sclerosis. Sleep Med. Jun 2019; 58:56-60.

**Table 1. Comparison between age, sex and marital status of both the studied group of relapsing remitting multiple sclerosis and control group:**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **MS patients N = 40** | | **Control N = 40** | | **Test** | | **P** |
| **Age (years)** |  | |  | |  | |  |
| Mean ± SD. | 35.23 ± 10.96 | | 31.53 ± 8.86 | | t= 1.660 | | 0.101 |
| Median | 37.0 | | 28.50 | |
| Min. – Max. | 17.0 – 63.0 | | 18.0 – 53.0 | |
| ≤40 year | 27 (67.5%) | | 31 (77.5%) | | X2=1.003 | | 0.317 |
| >40 year | 13 (32.5%) | | 9 (22.5%) | |
| **Sex** | **№** | **%** | **№** | **%** |  | |  |
| Male | 11 | 27.5 | 14 | 35.0 | x2= 0.524 | | 0.469 |
| Female | 29 | 72.5 | 26 | 65.0 |
| **Marital status** |  |  |  |  |  | |  |
| Single | 12 | 30.0 | 15 | 37.5 | x2= 2.907 | | 0.429 |
| Married | 25 | 62.5 | 25 | 62.5 |
| Widow | 1 | 2.5 | 0 | 0.0 |
| Divorced | 2 | 5.0 | 0 | 0.0 |
| **Residence** |  |  |  |  |  |  | |
| Rural | 10 | 25.0 | 25 | 62.5 | x2= 11.429 | 0.001\*\* | |
| Urban | 30 | 75.0 | 15 | 37.5 |
| **Education** |  |  |  |  |  |  | |
| University graduate | 21 | 52.5 | 23 | 57.5 | x2= 2.269 | 0.578 | |
| University student | 7 | 17.5 | 5 | 12.5 |
| Technical graduate | 10 | 25.0 | 12 | 30.0 |
| Technical student | 2 | 5.0 | 0 | 0.0 |
| **Occupation** |  |  |  |  |  |  | |
| Professional | 17 | 42.5 | 24 | 60.0 | x2= 5.592 | 0.389 | |
| Clerk | 4 | 10.0 | 3 | 7.5 |
| Student | 9 | 22.5 | 5 | 12.5 |
| Craftsman | 4 | 10.0 | 5 | 12.5 |
| Unemployed | 3 | 7.5 | 0 | 0.0 |
| Housewife | 3 | 7.5 | 3 | 7.5 |

P: Comparing between MS patients and control; \*, significant, p <0.05; \*\* high significant, p<0.01; \*\*\* very high significant, p<0.001.

**Table 2. Duration of illness in the studied patients with relapsing remitting multiple sclerosis:**

|  |  |
| --- | --- |
| **Duration of illness** | **MS patients N = 40** |
| Mean ± SE. | 5.26 ± 0.57 |
| Median (Min. – Max.) | 5.0 (0.50 – 19.0) |

Min.: Minimum, Max.: Maximum, SE: Standard Error.

**Table 3. Medications used in the studied patients with relapsing remitting multiple sclerosis:**

|  |  |  |
| --- | --- | --- |
| **Medication** | **MS patients N = 40** | |
| **No.** | **%** |
| **No medication** | 2 | 5.0 |
| **Dimethyl Fumerate** | 3 | 7.5 |
| **Fingolimod** | 19 | 47.5 |
| **Interferon b 1a** | 7 | 17.5 |
| **Interferon b 1b** | 1 | 2.5 |
| **Natalizumab** | 1 | 2.5 |
| **Ocreluzumab** | 1 | 2.5 |
| **Rituximab** | 5 | 12.5 |
| **Teriflunamide** | 1 | 2.5 |

**Table 4. The Expanded Disability Status Scale in the studied patients with relapsing remitting multiple sclerosis:**

|  |  |  |  |
| --- | --- | --- | --- |
| **EDSS** | **MS patients**  **N = 40** | | |
| **Mean ± SE.** | **Median** | **Min. – Max.** |
| 1.91 ± 0.30 | 1.50 | 0.0 – 6.0 |
| **Visual** | 0.18 ± 0.07 | 0.0 | 0.0 – 2.0 |
| **Brainstem** | 0.0 ± 0.0 | 0.0 | 0.0 – 0.0 |
| **Cerebellar** | 0.13 ± 0.06 | 0.0 | 0.0 – 2.0 |
| **Sensory** | 0.33 ± 0.08 | 0.0 | 0.0 – 2.0 |
| **Sphincter** | 0.50 ± 0.08 | 0.50 | 0.0 – 1.0 |
| **Mental** | 0.63 ± 0.11 | 1.0 | 0.0 – 2.0 |
| **Pyramidal** | 0.95 ± 0.22 | 2.0 | 0.0 – 4.0 |
| **Mild disability** (0–2.5) | 34 (85%) | | |
| **Moderate disability** (3.0–6.0) | 6 (15%) | | |

Min.: Minimum, Max.: Maximum, SE.: Standard Error

**Table 5. The physical health composite score and its subscales of the multiple sclerosis quality of life 54 questionnaire (MSQOL-54) in the studied patients with relapsing remitting multiple sclerosis :**

|  |  |  |  |
| --- | --- | --- | --- |
| **Physical composite score of the MSQOL-54 (PCS)** | **MS patients N = 40** | | **Max score** |
| Mean ± SE. | Median (Min. – Max.) |
| 50.28 ± 3.47 | 45.85 (8.80 – 100.0) | 100.0 |
| **Physical function** | 7.88 ± 0.87 | 8.50 (0.0 – 17.0) | 17.0 |
| **Role limitation due to physical problem** | 3.0 ± 0.75 | 0.0 (0.0 – 12.0) | 12.0 |
| **Pain** | 5.81 ± 0.51 | 5.31 (0.0 – 11.0) | 11.0 |
| **Energy** | 5.72 ± 0.41 | 5.76 (1.44 – 12.0) | 12.0 |
| **Health perception** | 8.05 ± 0.51 | 7.65 (2.55 – 17.0) | 17.0 |
| **Social function** | 7.48 ± 0.47 | 7.99 (1.99 – 12.0) | 12.0 |
| **Sexual function** | 6.70 ± 0.40 | 8.0 (0.0 – 8.0) | 8.0 |
| **Health distress due to physical problem** | 5.57 ± 0.50 | 4.40 (0.0 – 11.0) | 11.0 |

Min.: Minimum, Max.: Maximum, SE.: Standard Error

**Table 6. The mental health composite score and its subscales of the multiple sclerosis quality of life 54 questionnaire (MSQOL-54) in the studied patients with relapsing remitting multiple sclerosis:**

|  |  |  |  |
| --- | --- | --- | --- |
| **Mental composite of the MSQOL-54** | **MS patients N = 40** | | **Max score** |
| Mean ± SE. | Median (Min. – Max.) |
| 46.42 ± 3.36 | 39.3 (16.81 – 100.0) | 100.0 |
| **Cognitive function** | 5.44 ± 0.56 | 5.25 (0.0 – 15.0) | 15.0 |
| **Health distress due to emotional problems** | 7.09 ± 0.64 | 5.60 (0.0 – 14.0) | 14.0 |
| **Role limitation due to emotional problems** | 10.0 ± 1.85 | 0.0 (0.0 – 24.0) | 24.0 |
| **Emotional well being** | 13.57 ± 1.05 | 12.76 (1.16 – 29.0) | 29.0 |
| **Overall quality of life** | 11.19 ± 3.15 | 10.7 (4.5 – 18.0) | 18.0 |

Min.: Minimum, Max.: Maximum, SE.: Standard Error, U: Mann-Whitney,

**Table 7. Comparison between the studied patients with relapsing remitting multiple sclerosis and control group regarding The Pittsburgh Sleep Quality Index (PSQI):**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **PSQI** | **MS patients N = 40** | | **Control N = 40** | | **Test** | **P** |
| **Global sleep index** |  | |  | |  |  |
| Mean ± SE. | 7.40 ± 0.66 | | 5.98 ± 0.54 | | U= 643.5 | 0.130 |
| Median (Min. – Max.) | 8.0 (0.0 – 17.0) | | 6.0 (1.0 – 16.0) | |
| Good sleepers <5 | 10 | 25.0% | 13 | 32.5% | X2=0.549 | 0.459 |
| Bad sleepers ≥5 | 30 | 75% | 27 | 67.5% |
| **Subjective sleep quality** |  | |  | |  |  |
| Mean ± SE. | 1.53 ± 0.15 | | 1.23 ± 0.15 | | U= 674.5 | 0.202 |
| Median (Min. – Max.) | 1.0 (0.0 – 3.0) | | 1.0 (0.0 – 3.0) | |
| **Sleep latency** |  | |  | |  |  |
| Mean ± SE. | 1.70 ± 0.17 | | 1.55 ± 0.19 | | U= 705.5 | 0.346 |
| Median (Min. – Max.) | 2.0 (0.0 – 3.0) | | 1.50 (0.0 – 6.0) | |
| **Sleep duration** |  | |  | |  |  |
| Mean ± SE. | 0.98 ± 0.16 | | 0.85 ± 0.15 | | U= 749.5 | 0.603 |
| Median (Min. – Max.) | 1.0 (0.0 – 3.0) | | 1.0 (0.0 – 3.0) | |
| **Sleep efficiency** |  | |  | |  |  |
| Mean ± SE. | 0.58 ± 0.15 | | 0.20 ± 0.09 | | U= 630.5 | 0.031\* |
| Median (Min. – Max.) | 0.0 (0.0 – 3.0) | | 0.0 (0.0 – 3.0) | |
| **Sleep disturbance** |  | |  | |  |  |
| Mean ± SE. | 0.88 ± 0.11 | | 1.13 ± 0.11 | | U= 950.0 | 0.116 |
| Median (Min. – Max.) | 1.0 (0.0 – 2.0) | | 1.0 (0.0 – 2.0) | |
| **Sleep medication** |  | |  | |  |  |
| Mean ± SE. | 0.30 ± 0.12 | | 0.30 ± 0.13 | | U=  767.0 | 0.609 |
| Median (Min. – Max.) | 0.0 (0.0 – 3.0) | | 0.0 (0.0 – 3.0) | |
| **Daytime dysfunction** |  | |  | |  |  |
| Mean ± SE. | 0.95 ± 0.13 | | 0.73 ± 0.13 | | U= 656.0 | 0.130 |
| Median (Min. – Max.) | 1.0 (0.0 – 3.0) | | 1.0 (0.0 – 3.0) | |

Min.: Minimum, Max.: Maximum, SE.: Standard Error, U: Mann-Whitney, \*, significant, p <0.05; \*\* high significant, p<0.01; \*\*\* very high significant, p<0.001.